

FOI 1586

18/04/2023

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:**

**Berinert (Human C1-esterase inhibitor)**

**Cinryze (Human C1-esterase inhibitor)**

**Orladeyo (berotralstat)**

**Takhzyro (Lanadelumab)**

**Ruconest (Recombinant human C1-esterase inhibitor)**

**Firazyr (Icatibant)**

**Icatibant – any brand except Firazyr**

**Response:**

Berinert (Human C1-esterase inhibitor) <5

Cinryze (Human C1-esterase inhibitor) 0

Orladeyo (berotralstat) 0

Takhzyro (Lanadelumab) 0

Ruconest (Recombinant human C1-esterase inhibitor) 0

Firazyr (Icatibant) 0

Icatibant – any brand except Firazyr 0

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all

information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

**Q2. In the past 3 months [latest 3 months available] how many patients have received the following immunoglobulin treatments [for any disease]:**

**Cutaquig**

**Cuvitru**

**Gammanorm**

**Gammagard**

**Hizentra**

**Hyqvia**

**Intratect**

**Iqymune**

**Kiovig**

**Privigen**

**Octagam**

**Panzyga**

**Subgam**

**Any other normal immunoglobulin**

**Response:**

Cutaquig – 0

Cuvitru – 0

Gammanorm - 0

Gammagard - 0

Hizentra - 0

Hyqvia - 0

Intratect – 5 patients

Iqymune - 0

Kiovig – 0

Privigen – 29 patients

Octagam – <5 patients

Panzyga – 0

Subgam – 0

Any other normal immunoglobulin

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)